| Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease A Martin-Bastida, RJ Ward, R Newbould, P Piccini, D Sharp, C Kabba, ... Scientific reports 7 (1), 1398, 2017 | 339 | 2017 |
| Suicidal ideation in a European Huntington's disease population AAM Hubers, E Van Duijn, RAC Roos, D Craufurd, H Rickards, ... Journal of affective disorders 151 (1), 248-258, 2013 | 105 | 2013 |
| Frequency and characterization of movement disorders in anti-IgLON5 disease C Gaig, Y Compta, A Heidbreder, MJ Marti, MJ Titulaer, Y Crijnen, B Högl, ... Neurology 97 (14), e1367-e1381, 2021 | 94 | 2021 |
| Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease JY Lee, A Martin-Bastida, A Murueta-Goyena, I Gabilondo, N Cuenca, ... Nature Reviews Neurology 18 (4), 203-220, 2022 | 89 | 2022 |
| Patterns of grey matter loss associated with motor subscores in early Parkinson's disease X Li, Y Xing, A Martin-Bastida, P Piccini, DP Auer NeuroImage: Clinical 17, 498-504, 2018 | 74 | 2018 |
| Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: A cross‐sectional study of iron‐related magnetic resonance imaging susceptibility A Martin‐Bastida, NP Lao‐Kaim, C Loane, M Politis, AA Roussakis, ... European journal of neurology 24 (2), 357-365, 2017 | 74 | 2017 |
| Relationship between neuromelanin and dopamine terminals within the Parkinson’s nigrostriatal system A Martín-Bastida, NP Lao-Kaim, AA Roussakis, GE Searle, Y Xing, ... Brain 142 (7), 2023-2036, 2019 | 67 | 2019 |
| 11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study W Li, NP Lao‐Kaim, AA Roussakis, A Martín‐Bastida, N Valle‐Guzman, ... Movement Disorders 33 (1), 117-127, 2018 | 65 | 2018 |
| The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients S Metzger, C Walter, O Riess, RAC Roos, JE Nielsen, D Craufurd, ... PLoS One 8 (7), e68951, 2013 | 57 | 2013 |
| Neuromelanin in parkinsonian disorders: an update A Martin-Bastida, S Pietracupa, P Piccini International Journal of Neuroscience 127 (12), 1116-1123, 2017 | 44 | 2017 |
| Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease A Martin-Bastida, BS Tilley, S Bansal, SM Gentleman, DT Dexter, RJ Ward Journal of Neural Transmission 128, 15-25, 2021 | 40 | 2021 |
| Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review S Pietracupa, A Martin-Bastida, P Piccini Neurological Sciences 38, 2095-2101, 2017 | 38 | 2017 |
| Neuromelanin‐MRI to quantify and track nigral depigmentation in Parkinson's disease: a multicenter longitudinal study using template‐based standardized analysis Y Xing, AH Sapuan, A Martín‐Bastida, S Naidu, C Tench, J Evans, G Sare, ... Movement Disorders 37 (5), 1028-1039, 2022 | 28 | 2022 |
| Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson’s disease W Li, NP Lao-Kaim, AA Roussakis, A Martín-Bastida, N Valle-Guzman, ... NeuroImage: Clinical 28, 102409, 2020 | 28 | 2020 |
| Is chelation therapy a potential treatment for Parkinson’s disease? RJ Ward, DT Dexter, A Martin-Bastida, RR Crichton International journal of molecular sciences 22 (7), 3338, 2021 | 27 | 2021 |
| MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy IN Petrovic, A Martin-Bastida, L Massey, H Ling, SS O’Sullivan, ... Journal of neurology 260, 1031-1036, 2013 | 25 | 2013 |
| Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders I Navalpotro-Gomez, R Dacosta-Aguayo, F Molinet-Dronda, ... European Journal of Nuclear Medicine and Molecular Imaging 46, 2065-2076, 2019 | 16 | 2019 |
| Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep 7: 1398 A Martin-Bastida, RJ Ward, R Newbould, P Piccini, D Sharp, C Kabba, ... | 16 | 2017 |
| Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017; 7 (1): 1398 A Martin-Bastida, RJ Ward, R Newbould, P Piccini, D Sharp, C Kabba, ... Cited Here, 0 | 15 | |
| Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with 11C-BU99008 PET MA Mohamed, Z Zeng, M Gennaro, NP Lao-Kaim, JFM Myers, ... Brain Communications 4 (5), fcac199, 2022 | 12 | 2022 |
Andreas Antonios RoussakisImperial College Londonایمیل تأیید شده در imperial.ac.uk
